YOLFTbeta
GRI Bio Inc.

GRI Bio Inc.

GRI · NASDAQ · Healthcare / Biotechnology

1.70USD-0.12 (-6.59%)

Price History

Full chart

Market Stats

Previous Close1.82
Open1.79
Day Range1.70 – 1.83
52-Week Range1.36 – 64.12
Volume21.79K
Market Cap4.48M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.86
Dividend Yield0.00%
Beta-0.55
50-Day Avg1.77
200-Day Avg3.63

About

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. W. Marc Hertz Ph.D.
  • Employees3
  • Headquarters2223 Avenida de la Playa, La Jolla, CA, United States, 92037, USA
  • Websitehttps://www.gribio.com

Leadership

  • Dr. W. Marc Hertz Ph.D.Co-Founder, CEO, President & Director · b. 1971
  • Dr. Vipin Kumar Chaturvedi Ph.D.Co-Founder & Chief Scientific Officer · b. 1960
  • Ms. Leanne M. KellyCFO & Corporate Secretary · b. 1977
  • Dr. Albert Agro Ph.D.Co-Founder & Chief Medical Officer · b. 1965

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--100.00K0021.77M22.54M0
Growth (%)----100.00%--+3.54%-100.00%
Cost of Revenue612735100.00K73.00K50.00K57.00K4.00K4.00K
Gross Profit-612-735100.00K-73.00K-50.00K-57.00K-4.00K-4.00K
Gross Margin--100.00%---0.26%-0.02%-
Operating Expense4.31M3.15M1.56M989.00K2.19M11.33M8.23M11.97M
Operating Income-4.31M-3.15M-1.46M-1.06M-2.24M-11.39M-8.23M-11.98M
Operating Margin---1459.00%---52.31%-36.54%-
EBITDA-4.31M-3.27M-1.46M-1.06M-2.56M-10.95M-8.23M-11.97M
EBITDA Margin---1456.00%---50.31%-36.52%-
Net Income-4.31M-3.46M-2.53M-1.56M-3.22M-13.04M-8.21M-11.96M
Net Income Margin---2531.00%---59.89%-36.41%-
R&D3.51M1.88M264.00K249.00K242.00K3.23M3.77M6.82M
R&D as % of Total Revenue--264.00%--14.85%16.72%-
Interest Expense-197.03K34.00K547.00K653.00K2.08M6.00K-
Interest Expense % of Total Revenue--34.00%--9.56%0.03%-

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets639.23K4.28M955.00K218.00K383.00K2.96M5.74M8.67M
Total Liabilities486.29K1.06M2.41M4.94M2.01M2.70M1.71M2.66M
Total Equity152.94K3.21M-1.45M-4.72M-1.63M259.00K4.03M6.01M
Cash612.65K3.82M109.00K90.00K9.00K1.81M5.03M8.23M
Total Debt-340.02K336.00K3.61M673.00K14.00K119.00K71.00K
Net Debt-612.65K-3.48M227.00K3.52M664.00K-1.79M-4.91M-8.16M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.37M-2.88M-3.71M-8.31M-1.08M-8.99M-8.61M-10.19M
Investing Cash Flow-2.20K--2.00K-3.84M-3.00K-8.00K--3.00K
Financing Cash Flow2.99M6.09M-4.00K15.75M1.01M10.80M11.83M13.39M
Capital Expenditure2.21K52.00K03.00K8.00K03.00K
Free Cash Flow-2.37M-2.88M-3.71M-8.31M-1.09M-9.00M-8.61M-10.19M
Dividends Paid----3.45M2.92M--
FCF to OCF100.09%100.00%100.05%100.00%100.28%100.09%100.00%100.03%
Dividend Paid to FCF-----316.82%-32.40%--

Earnings

Report DateOct 23, 2020Jan 28, 2021May 13, 2021Sep 1, 2021Nov 12, 2021Feb 14, 2022May 9, 2022Jul 28, 2022Nov 3, 2022Feb 23, 2023May 10, 2023Aug 8, 2023Nov 14, 2023Feb 22, 2024May 13, 2024Aug 14, 2024Nov 14, 2024Mar 26, 2025May 15, 2025Aug 14, 2025Nov 14, 2025Jan 30, 2026May 13, 2026Aug 14, 2026Nov 13, 2026
EPS Estimate0.000.000.000.000.00-0.22-0.22-0.23-0.25-0.290.00------347.48-5.44-105.98-36.68-31.08-29.26-3.74-1.20-0.84
EPS Actual-0.19-0.14-0.46-0.34-0.18-0.22-0.22-0.20-0.09-0.12-5.33-4316.37-0.52-3.10-3.10-4.92-318.92-7.34-5.80-36.68-35.84-116.61-1.61-0.91-
Surprise-----0.00%0.00%13.04%64.00%58.62%------8.22%-35.00%94.53%0.00%-15.32%-298.53%56.95%24.17%-
Timing------------After-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-market-

Key Statistics & Ratios

Market Cap4.48M
Enterprise Value-6.27M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.45
EPS-2.86
Book Value4.70
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-9.68M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-142.02%
Return on Assets-70.93%
Shares Outstanding2.19M
Shares Float2.19M
Beta-0.55
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 18.50
  • Strong Buy
    1
  • Buy
    1

Ownership Breakdown

Institutions
4.28%
Insiders
0.38%
Retail / Other
95.34%

Top Institutional Holders

  • Geode Capital Management, LLC
    18.44K0.84%
  • Citadel Advisors Llc
    13.38K0.61%
  • UBS Group AG
    8.72K0.40%
  • Tower Research Capital LLC
    1.06K0.05%
  • BlackRock Inc
    70.00%
  • SBI Securities Co Ltd
    40.00%
  • Danske Bank A/S.
    20.00%
  • Bank of America Corp
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    9.17K0.42%
  • Fidelity Series Total Market Index
    8720.04%

Stock Splits

  • Jan 26, 20261:28
  • Feb 24, 20251:17
  • Jun 18, 20241:13
  • Jan 30, 20241:7
  • Apr 24, 20231:30